Esperion Therapeutics, Inc. ESPR
At closeJul 13, 2026, 4:00 PM EDT
After hours · Jul 13, 4:00 PM ET
52-week range unavailable
- YTD
- -14.05%
- 1 year
- +211.76%
- Market cap
- 661.15M
- Revenue (ttm)
- 295.45M
- Profit margin
- -29.37%
- Shares out
- 197.04M
- Forward P/E
- 11.20
- YTD return
- -14.05%
- 1-year return
- +211.76%
- Open
- 3.18
- Previous close
- 3.18
- Day's range
- 3.18 – 3.18
- Beta
- 0.95
- Analysts
- Buy
- Price target
- 7.51 (+136.1%)
2Y +0.68 (+27.20%)
Key statistics
- Enterprise value
- 555.75M
- PEG ratio
- 0.00
- Price / sales
- 1.49
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 52.00%
- Free cash flow
- -8.95M
- Total cash
- 144.72M
- Total debt
- 268.96M
- Return on equity
- 0.00%
- Short % of float
- 15.52%
- 50-day average
- 2.41
- 200-day average
- 2.24
Analyst view
Consensus: buy
- Target (low)
- 2.05
- Target (mean)
- 7.51
- Target (high)
- 16.00
- Strong buy3
- Buy2
- Hold1
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.12529.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.14 | -0.15 | -0.01 | -7.14% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | -0.05 | +0.10 | +66.67% |
| May 7, 2024 | Mar 1, 2024 | -0.08 | 0.34 | +0.42 | +525.00% |
| Feb 27, 2024 | Dec 1, 2023 | -0.53 | -0.50 | +0.03 | +5.66% |
| Nov 7, 2023 | Sep 1, 2023 | -0.42 | -0.37 | +0.05 | +11.90% |
| Aug 1, 2023 | Jun 1, 2023 | -0.63 | -0.46 | +0.17 | +26.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Dec 13, 2024 | Needham | reit | Buy | Buy |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- esperion.com
News
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio 
10 Health Care Stocks With Whale Alerts In Today’s Session 
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results 
Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday 
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday 
Earnings Scheduled For March 10, 2026 
H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on ESPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARROLL J MARTIN | Director | Stock Award(Grant) | May 22, 2024 | 64,650 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | May 22, 2024 | 28,150 |
| FOODY JOANNE MICALE | Officer | Sale | Jul 16, 2024 | 272,862 |
| FUHRMAN ALAN CPA | Director | Stock Award(Grant) | May 22, 2024 | 53,404 |
| GOTTO ANTONIO M JR | Director | Stock Award(Grant) | May 22, 2024 | 51,599 |
| HALLADAY BENJAMIN | Chief Financial Officer | Sale | Dec 16, 2024 | 240,691 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Advisors LP | 11.85% | 23,346,013 | 52.30M | Sep 29, 2024 |
| Blackrock Inc. | 7.24% | 14,264,975 | 31.95M | Sep 29, 2024 |
| Vanguard Group Inc | 6.62% | 13,043,077 | 29.22M | Sep 29, 2024 |
| Bellevue Group AG | 5.05% | 9,944,064 | 22.27M | Sep 29, 2024 |
| Two Seas Capital Lp | 3.34% | 6,584,278 | 14.75M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.20% | 4,331,314 | 9.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 3.39% | 6,675,165 | 14.95M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.14% | 6,179,587 | 13.84M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 4,866,712 | 10.90M | Oct 30, 2024 |
| Wasatch Small Cap Growth Fund | 2.23% | 4,397,143 | 9.85M | Sep 29, 2024 |
| Wasatch Microcap Fund | 2.14% | 4,211,030 | 9.43M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 2,575,610 | 5.77M | Sep 29, 2024 |